{"title":"Diagnostic Approach to Abnormal Alkaline Phosphatase Value","authors":"Salvatore Minisola MD , Cristiana Cipriani MD, PhD , Luciano Colangelo MD, PhD , Giancarlo Labbadia MD , Jessica Pepe MD, PhD , Per Magnusson (Professor)","doi":"10.1016/j.mayocp.2024.11.019","DOIUrl":"10.1016/j.mayocp.2024.11.019","url":null,"abstract":"<div><div>Alkaline phosphatase (ALP) is abundantly represented in nature, being fundamental for a number of processes. In addition to its fundamental function in skeletal mineralization, its roles in the pathogenesis of other diseases are being explored. The measurement of total ALP activity in serum or in plasma is a useful biomarker in clinical practice. Indeed, routine measurement of serum total ALP is a long-standing established part of initial biochemical evaluation of patients both in the hospital setting and on an ambulatory basis. Raised or reduced values of this enzyme activity are indicative of a number of diseases, most commonly affecting the skeleton and the biliary tract. Electrophoretic assays are preferable for visualizing and investigating the cause of increased serum total ALP activities, and bone ALP immunoassays are preferable for investigating and monitoring individuals with bone and mineral metabolic abnormalities. Here, we give a holistic vision of this fundamental enzyme, suggesting a clinical approach to the identification of diseases causing abnormal values. Finally, a therapeutic role has emerged as substitutive therapy in patients with hypophosphatasia, even though ongoing and future studies are exploring its role in other therapeutic areas. This narrative review was based on articles found by searching PubMed from its inception until July 2024 for the terms <em>alkaline phosphatases</em>, <em>isozymes</em>, <em>isoforms</em>, <em>bone alkaline phosphatase</em>, <em>liver alkaline phosphatase</em>, <em>intestinal alkaline phosphatase</em>, <em>placental alkaline phosphatase</em>, <em>liver function tests</em>, γ-<em>glutamyltransferase</em>, <em>skeletal diseases</em>, and <em>liver diseases</em>. We limited our research to papers published in the English language, with emphasis placed on those describing differential diagnosis whenever available.</div></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"100 4","pages":"Pages 712-728"},"PeriodicalIF":6.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dong-Seon Kang MD , Daehoon Kim MD , Eunsun Jang MS , Hee Tae Yu MD , Tae-Hoon Kim MD , Jae-Sun Uhm MD , Jung-Hoon Sung MD , Hui-Nam Pak MD , Moon-Hyoung Lee MD , Pil-Sung Yang MD , Boyoung Joung MD
{"title":"Early Rhythm Control for Atrial Fibrillation in Patients With End-Stage or Chronic Kidney Disease","authors":"Dong-Seon Kang MD , Daehoon Kim MD , Eunsun Jang MS , Hee Tae Yu MD , Tae-Hoon Kim MD , Jae-Sun Uhm MD , Jung-Hoon Sung MD , Hui-Nam Pak MD , Moon-Hyoung Lee MD , Pil-Sung Yang MD , Boyoung Joung MD","doi":"10.1016/j.mayocp.2024.10.006","DOIUrl":"10.1016/j.mayocp.2024.10.006","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the benefits and risks of early rhythm control (ERC) in patients with atrial fibrillation (AF) and chronic kidney disease (CKD).</div></div><div><h3>Patients and Methods</h3><div>This population-based cohort study included 5224 patients with AF (58.2% male, median age 70 years) with end-stage kidney disease (ESKD; n=1660) and CKD stage 3 to 4 (n=3564), who underwent ERC or rate control between January 1, 2005, and December 31, 2015. A primary outcome consisted of cardiovascular death, ischemic stroke, heart failure–related hospitalization, and acute myocardial infarction.</div></div><div><h3>Results</h3><div>During a median follow-up of 3.5 years, compared with rate control, ERC was associated with a reduced risk of the primary outcome (hazard ratio [HR], 0.85; 95% CI, 0.74 to 0.98) without an increase in the composite safety outcome in CKD stage 3 to 4 (HR, 0.99; 95% CI, 0.86 to 1.13). In patients with ESKD, there was no difference between rate control and ERC in the primary outcome (HR, 0.97; 95% CI, 0.81 to 1.17) but an increase in composite safety outcome (HR, 1.29; 95% CI, 1.11 to 1.50). During follow-up, 65.0% of patients with ESKD and 57.3% with CKD stage 3 to 4 failed to maintain ERC. In the on-treatment (HR, 0.79; 95% CI, 0.62 to 0.99) and time-varying regression (HR, 0.81; 95% CI, 0.68 to 0.98) analyses, ERC was associated with a lower risk of primary outcome even in patients with ESKD.</div></div><div><h3>Conclusion</h3><div>Early rhythm control revealed a modest risk-benefit profile in patients with ESKD compared with CKD stage 3 to 4, with poor adherence to ERC playing a major role. Therefore, an approach tailored to renal function should be considered for choosing AF treatment strategies.</div></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"100 4","pages":"Pages 634-646"},"PeriodicalIF":6.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anthony H. Kashou MD, Nandan S. Anavekar MB, BCh, Joseph G. Murphy MD
{"title":"The Debris Field of Scientific Publications Authored by Artificial Intelligence","authors":"Anthony H. Kashou MD, Nandan S. Anavekar MB, BCh, Joseph G. Murphy MD","doi":"10.1016/j.mayocp.2025.02.013","DOIUrl":"10.1016/j.mayocp.2025.02.013","url":null,"abstract":"","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"100 4","pages":"Pages 596-598"},"PeriodicalIF":6.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jordan S. Nunnelee MD , Mackenzie D. Maberry MD , Ronald S. Go MD
{"title":"33-Year-Old Man With Fatigue","authors":"Jordan S. Nunnelee MD , Mackenzie D. Maberry MD , Ronald S. Go MD","doi":"10.1016/j.mayocp.2024.03.014","DOIUrl":"10.1016/j.mayocp.2024.03.014","url":null,"abstract":"","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"100 4","pages":"Pages 729-734"},"PeriodicalIF":6.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chen Huang BA , Yahang Liu BS , Ruilang Lin BS , Ce Wang PhD , Ye Yao PhD , Guoyou Qin PhD , Yiliang Zhang MD , Yongfu Yu PhD
{"title":"Accelerometer-Derived \"Weekend Warrior\" Physical Activity and All-Cause and Cause-Specific Mortality","authors":"Chen Huang BA , Yahang Liu BS , Ruilang Lin BS , Ce Wang PhD , Ye Yao PhD , Guoyou Qin PhD , Yiliang Zhang MD , Yongfu Yu PhD","doi":"10.1016/j.mayocp.2024.10.022","DOIUrl":"10.1016/j.mayocp.2024.10.022","url":null,"abstract":"<div><h3>Objective</h3><div>To examine the association of “weekend warrior” (WW) pattern and physical activity distributed throughout the week with mortality risk.</div></div><div><h3>Participants and Methods</h3><div>In this cohort study of 95,468 participants in the UK Biobank from 2013 through 2015, participants were grouped by accelerometer-derived physical activity levels: inactive (moderate to vigorous physical activity [MVPA] <150 min/wk using World Health Organization guidelines), active WW (≥150 minutes of MVPA per week and ≥50% of total MVPA over 1 to 2 days), and active regular (≥150 minutes of MVPA but not active WW). Cox regression analyzed associations of activity patterns with all-cause mortality and 10 categories of cause-specific mortality and whether the association differed by sedentary time (<span><math><mrow><mo>≤</mo></mrow></math></span>6, 7 to 12, or ≥13 hours) and light physical activity (<span><math><mrow><mo>≤</mo></mrow></math></span>60, 61 to 150, or ≥151 min/d).</div></div><div><h3>Results</h3><div>During the median 7.92 years of follow-up, 3539 deaths occurred. Compared with the inactive participants, the hazard ratio for all-cause mortality was 0.74 (95% CI, 0.68 to 0.82) in active regular participants and 0.72 (95% CI, 0.67 to 0.78) in active WW participants. Similar risk reductions were noted in most cause-specific deaths, especially for those from cancer, cardiovascular disease, and respiratory diseases. These benefits were more profound among participants with 13 or more hours of sedentary time (active regular: 0.58 [0.41 to 0.83]; active WW: 0.70 [0.55 to 0.88]) or 60 min/d or less of light physical activity (active regular: 0.59 [0.42 to 0.83]; active WW: 0.47 [0.35 to 0.63]). A similar reduction in all-cause mortality risk was observed across different age groups regardless of activity frequency and timing.</div></div><div><h3>Conclusion</h3><div>Physical activity evenly distributed throughout the week and concentrated within 1 to 2 days are both associated with similar lower risks of all-cause mortality and most categories of cause-specific mortality.</div></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"100 4","pages":"Pages 609-621"},"PeriodicalIF":6.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}